KYTX

Kyverna Therapeutics, Inc.

Recommendation Details

PortfolioHealthcare

DateNov 12, 2026

ForecastQ Daily Probabilities

53.2%

42.0%

37.4%

Company Description

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Recent News & Events

Near-term catalysts skew negative on securities litigation overhang, but positive miv-cel data publication and an imminent Q3 earnings report plus Jefferies conference appearance create two-sided volatility.

Clinical Data Publication

Miv-cel SPS registrational data published in JAMA Neurology

Kyverna announced publication of the KYSA-8 registrational trial primary analysis in JAMA Neurology, showing statistically significant improvements across all primary and secondary endpoints at 16 weeks with a well-tolerated safety profile. Peer-reviewed validation of the lead asset ahead of the rolling BLA completion supports the regulatory narrative and could draw incremental institutional interest.

Kyverna Therapeutics Press Release

Legal Investigation

KSF initiates investigation of Kyverna officers and directors

Kahn Swick & Foti announced an investigation into Kyverna's officers and directors tied to a securities lawsuit alleging the 2024 IPO registration statement misstated or omitted adverse KYV-101 clinical data. Renewed litigation headlines can pressure sentiment and raise perceived governance risk in the near term.

Business Wire

Earnings Report

Q3 2026 earnings expected imminently

Analysts expect a Q3 2026 net loss of roughly $0.69 per share with negligible revenue. Investors will focus on confirmation that the rolling BLA submission for miv-cel in SPS remains on track for Q4 2026 completion and any FDA review commentary; a slip or cash burn surprise would be negative.

Tickeron

Conference Presentation

Management to present at Jefferies London Healthcare Conference

Kyverna management will present at the Jefferies Global Healthcare Conference in London on November 19, 2026. Conference appearances offer a venue for BLA timeline updates and pipeline commentary that can move the stock, particularly given proximity to the Q3 report.

Kyverna Therapeutics Press Release

Regulatory Milestone Guidance

Rolling BLA completion guided for Q4 2026

Kyverna has submitted the CMC module of its rolling BLA for miv-cel in SPS and remains on track to complete submission in Q4 2026, with plans to seek priority review under RMAT. Confirmation of this timeline is the key near-term regulatory catalyst and underpins the potential 2027 launch thesis.

SEC Filing (EX-99.1)

KYTX

KYTX

Company Information

Recommendation Details

Company Description

Recent News & Events

Miv-cel SPS registrational data published in JAMA Neurology

KSF initiates investigation of Kyverna officers and directors

Q3 2026 earnings expected imminently

Management to present at Jefferies London Healthcare Conference

Rolling BLA completion guided for Q4 2026